iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) has seen dramatic gains this month. While the stock is down about 4% thus far today on profit taking, there’s a strong likelihood that we will see further gains ahead. At the end of the day, there are several catalysts around the corner that could send this stock to the moon. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Just In Case You Haven’t Been Watching IBIO Stock

If you haven’t been watching iBio as of late, you’ve been missing out. The stock has gained in multiples after announcing a partnership with CC Pharming to produce a Wuhan coronavirus vaccine. The partnership comes with two key competitive advantages:

  • CC Pharming – First and foremost, CC Pharming has produced vaccines for the SARS-coronavirus. This is a cousin virus to today’s epidemic-causing COVID-19. With experience in the successful creation of a vaccine for a similar virus, a competitive advantage is born.
  • IBIO – On the iBio side of the coin, the company has the FastPharming Facility. This facility was specifically developed to be able to produce vaccines and other therapeutic agents quickly enough to combat epidemics and pandemics. With the speed at which vaccines can be produced at the FastPharming facility, yet another competitive advantage is born.

For more details, click here.

Catalysts To Watch For Ahead

Given recent news from IBIO, there are likely several catalysts ahead that investors should be watching out for. In my view, these include:

  • Partnership Update – Any positive update on the partnership with CC Pharming has the potential to send this stock through the roof.
  • Vaccine Development – At some point, it’s likely that the company will announce that it has developed a viable vaccine candidate in its partnership and is pushing the candidate into clinical trials. This could also send the stock soaring.
  • Manufacturing Partnerships – IBIO and CC Pharming aren’t the only companies working to develop a coronavirus vaccine out there. In fact, there are tons of them. However, iBio is the only company with access to the FastPharming Facility. So, we could start to hear more about potential manufacturing partnerships with other vaccine developers.
  • Funding – Recently, the United States government passed a bill to provide $8 billion in funding to fight the spread of the Wuhan coronavirus. Considering the competitive advantages here, IBIO is a likely recipient of some of these funds. Soon, I expect that the company will announce the receipt of funds as part of this program, sending the stock skyward.

There you have it my friends. In my view, the gains that we’ve seen from iBio are just the beginning. With multiple catalysts likely around the corner, picking up shares at the end of this profit taking run may be a very big opportunity!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.